The Scan by 2 Minute Medicine® is a new pop-culture medical newsletter designed to bring a physician perspective to trending ...
Phase 2 Placebo-Controlled Trial of Two Vaccines to Prevent Ebola in Liberia In 2014, two candidate Ebola virus (EBOV) vaccines ...
1. By day 28, all recipients of a recombinant vesicular stomatitis virus (rVSV) vaccine, at each of the three doses ...
A population-based study of cardiovascular mortality following early-stage breast cancer The disease-specific survival for women treated for early-stage breast cancer ...
1. Chimpanzee adenovirus 3 (ChAd3) vaccination boosted with modified vaccinia Ankara (MVA) elicited superior B- and T-cell immune responses to ...
1. Zaire ebolavirus-glycoprotein-specific antibody responses were detected in all participants receiving vaccination doses from 300,000 to 50 million plaque-forming units ...
1. Artesunate-amodiaquine (AA) treated Ebola patients had a significantly lower risk of death than artemether-lumefantrine (AL) treated patients. 2. ...
1. Patients with Ebola virus disease (EVD) who received convalescent plasma transfusions had a 7% less risk of mortality ...
1. An Ebola vaccine candidate (VSV-EBOV) conferred protection from the 2014/15 West African Ebola virus strain (EBOV-Makona) in macaques when ...
1. Interim results from an open-label cluster-randomized trial of the novel rVSV-ZEBOV Ebola virus vaccine showed 100% vaccine efficacy in ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.
Subscribe for free today!